- The first FDA approved 3-D printed prescription drug is now available on the U.S. market, Aprecia Pharmaceuticals announced Tuesday.
- SPRITAM, approved by the FDA in 2015, treats partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures and can disintegrates in the patient's mouth.
- SPRITAM is now available in four unit-dose strengths - 250 mg, 500 mg, 750 mg, and 1,000 mg.
“As we explored potential applications for our 3D printing technology in prescription drug products, it was important that we identified disease areas with a real need for patient-friendly forms of medication,” Aprecia CEO Don Wetherhold said in a prepared statement.
According to the CDC, about 2.4 million people were living with active epilepsy in 2013 - about 1% of adults 18 years or older.
In January, Aprecia completed a fundraising round led by Deerfield Management Co. with $35 million, the Philadelphia Business Journal reports.
Just last month, a team of researchers at Wake Forest School of Medicine devised a way to 3-D print human-scale bone, muscle, and cartilage, Healthcare Dive previously reported.